The theranostic market currently faces a shortage of high-quality development and manufacturing space capable of meeting the volume needs of radiopharmaceutical treatments used in late-stage clinical trials, as well as those in the development pipeline that will soon receive regulatory approvals. Nucleus’ new space will help fulfill both of those needs, allowing its partners to produce crucial theranostics across the country. Nucleus will also build a new facility in Philadelphia, PA for a total of more than 100,000-square-feet of capacity between the two new sites. Once operational, the sites will allow Nucleus to more fully realize its commitment to a nationwide network capable of serving the ever-growing demand for theranostics across the U.S. ahead of the Rochester, MN site that will come online in early 2025.
“To reach their full potential as treatments for millions of patients with limited options, theranostic radiopharmaceuticals must be available close to those who need them,” said Nucleus RadioPharma CEO Charles S. Conroy. “Our expansion will significantly improve patient access to these life-saving treatments and expedite clinical trials, potentially reducing time-to-market for new therapies by up to 30%.”
“Nucleus RadioPharma’s new manufacturing facility highlights Arizona’s thriving bioscience industry that’s developing cutting-edge innovations to improve people’s lives,” said Sandra Watson, President and CEO of the Arizona Commerce Authority. “With this new facility, Nucleus RadioPharma strengthens Arizona’s bioscience leadership while developing breakthrough treatments for patients. We’re grateful to Nucleus RadioPharma for their commitment to Arizona.”
“We’re excited to welcome Nucleus RadioPharma’s new facility to Mesa,” said Mesa Mayor John Giles. “Their investment brings dozens of well-paying jobs to our city, boosting our local economy and enhancing our reputation as a hub for innovation. This expansion opens new doors for our local workforce and underscores Mesa’s role in supporting cutting-edge technology development. I’m confident this partnership will have long-lasting benefits for our community as well as patients across the nation.”
“Cancer has impacted countless families, including mine, so today’s announcement resonates deeply with me,” said Mesa Councilmember Scott Somers. “Nucleus RadioPharma’s presence in Mesa isn’t just about economic growth—it’s about hope. This facility will create advanced manufacturing jobs and ensure the steady supply of life-saving medications to help more people fight and overcome this disease.”
